Goldman Sachs analyst Nathan Rich started Idexx Laboratories with a Neutral rating and $277 price target. The analyst thinks the company is well positioned to benefit from the continued growth of diagnostics as an increasingly important source of revenue for the vet practice. However, he believes this is fully reflected in Idexx's current valuation. Rich initiated coverage of the Animal Health industry and recommends a selective approach. The positive long-term fundamental drivers of the industry, particularly in the companion animal space, appear increasingly reflected in valuations, the analyst tells investors in a research note.